drugset

drugset / Trial / NCT07265752

Tirzepatide for the Treatment of Cannabis Use Disorder

NCT07265752 ↗

Phase 2 Not yet recruiting 6 enrolled Brigham and Women's Hospital

RandomizedCrossoverQuadruple-blindTreatment

Summary

This is a pilot randomized cross-over trial to examine the effects of tirzepatide on cue-reactivity among individuals with cannabis use disorder.

Timeline

Start: 2026-07-01
Primary completion: 2028-06-30
Completion: 2028-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tirzepatide	Peptide	2.5 mg	Subcutaneous

Indications